Last quarter (Q4 2023), Oric Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Oric Pharmaceuticals's net income was $-28.33M. See Oric Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 110.78M	$ 110.78M	$ 91.77M	$ 78.87M	$ 49.34M	$ 28.57M
Operating Income	$ -110.78M	$ -110.78M	$ -91.77M	$ -78.87M	$ -49.34M	$ -28.57M
Net Non Operating Interest Income Expense	-	-	$ 2.65M	$ 141.00K	$ 306.00K	$ 1.40M
Other Income Expense	$ -10.08M	$ -10.08M	-	$ -15.00K	$ -24.67M	$ 289.00K
Pretax Income	$ -100.70M	$ -100.70M	$ -89.12M	$ -78.72M	$ -73.70M	$ -26.88M
Tax Provision	$ -6.93M	$ -6.93M	$ -6.00M	$ -30.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -100.70M	$ -100.70M	$ -89.12M	$ -78.72M	$ -73.70M	$ -26.88M
Basic EPS	$ -1.96	$ -1.96	$ -2.25	$ -2.07	$ -3.36	$ -1.40
Diluted EPS	$ -1.96	$ -1.96	$ -2.25	$ -2.07	$ -3.36	$ -1.40
Basic Average Shares	$ 205.80M	$ 51.45M	$ 39.66M	$ 37.95M	$ 21.94M	$ 19.14M
Diluted Average Shares	$ 205.80M	$ 51.45M	$ 39.66M	$ 37.95M	$ 21.94M	$ 19.14M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 110.78M	$ 110.78M	$ 91.77M	$ 78.87M	$ 49.34M	$ 28.57M
Net Income From Continuing And Discontinued Operation	$ -100.70M	$ -100.70M	$ -89.12M	$ -78.72M	$ -73.70M	$ -26.88M
Normalized Income	$ -73.52M	$ -107.63M	$ -95.13M	-	$ -48.86M	$ -26.88M
Interest Expense	-	-	-	-	-	-
EBIT	$ -100.70M	$ -100.70M	$ -89.12M	$ -78.72M	$ -49.34M	$ -28.57M
EBITDA	$ -105.87M	$ -105.87M	$ -89.16M	$ -76.47M	$ -48.37M	$ -27.54M

Currency in USD

Oric Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing